{"id":37427,"date":"2025-07-16T16:00:29","date_gmt":"2025-07-16T08:00:29","guid":{"rendered":"https:\/\/flcube.com\/?p=37427"},"modified":"2025-07-16T16:00:29","modified_gmt":"2025-07-16T08:00:29","slug":"sino-biopharmaceutical-acquires-majority-stake-in-lanova-medicines-for-usd-950-92-million","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37427","title":{"rendered":"Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million"},"content":{"rendered":"\n<p>China-based Sino Biopharmaceutical Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) announced the acquisition of a 95.09% stake in Shanghai-based LaNova Medicines Ltd for USD 950.92 million. After deducting LaNova&#8217;s USD 450 million cash and equivalents, the net transaction value stands at USD 500.9 million. Sino Bio, which previously held 4.91% of LaNova, will gain full ownership post-transaction.<\/p>\n\n\n\n<p><strong>LaNova&#8217;s Technological Edge<\/strong><br>LaNova Medicines boasts globally-leading antibody discovery and ADC technology platforms. These include the tumor microenvironment-specific antibody platform (LMTME), difficult-to-drug target antibody platform (LM-Abs), next-gen antibody-drug conjugate platform (LM-ADC), and immune cell engager platform (LM-TCE). The company&#8217;s innovative platforms position it at the forefront of cancer therapy development.<\/p>\n\n\n\n<p><strong>Pipeline and Licensing Success<\/strong><br>LaNova&#8217;s pipeline has gained significant international recognition. In 2023, LM-305 (anti-GPRC5D ADC) was licensed to AstraZeneca for USD 600 million. More recently, in 2024, LM-299 (PD-1\/VEGF bispecific) was licensed to Merck for over USD 3 billion. These achievements highlight LaNova&#8217;s strength in developing cutting-edge therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2025071500771_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025071500771_c.\"><\/object><a id=\"wp-block-file--media-c9229f06-e51a-4445-ae78-62fdeaa4ce11\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2025071500771_c.pdf\">2025071500771_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2025071500771_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c9229f06-e51a-4445-ae78-62fdeaa4ce11\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acquisition of a 95.09% stake in Shanghai-based&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37429,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,20,908,1376,313],"class_list":["post-37427","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-finance","tag-hkg-1177","tag-lanova-medicines","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acquisition of a 95.09% stake in Shanghai-based LaNova Medicines Ltd for USD 950.92 million. After deducting LaNova&#039;s USD 450 million cash and equivalents, the net transaction value stands at USD 500.9 million. Sino Bio, which previously held 4.91% of LaNova, will gain full ownership post-transaction.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37427\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million\" \/>\n<meta property=\"og:description\" content=\"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acquisition of a 95.09% stake in Shanghai-based LaNova Medicines Ltd for USD 950.92 million. After deducting LaNova&#039;s USD 450 million cash and equivalents, the net transaction value stands at USD 500.9 million. Sino Bio, which previously held 4.91% of LaNova, will gain full ownership post-transaction.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37427\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-16T08:00:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1604.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37427#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37427\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million\",\"datePublished\":\"2025-07-16T08:00:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37427\"},\"wordCount\":166,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37427#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1604.webp\",\"keywords\":[\"Biotech\",\"Finance\",\"HKG: 1177\",\"LaNova Medicines\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37427#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37427\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37427\",\"name\":\"Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37427#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37427#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1604.webp\",\"datePublished\":\"2025-07-16T08:00:29+00:00\",\"description\":\"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acquisition of a 95.09% stake in Shanghai-based LaNova Medicines Ltd for USD 950.92 million. After deducting LaNova's USD 450 million cash and equivalents, the net transaction value stands at USD 500.9 million. Sino Bio, which previously held 4.91% of LaNova, will gain full ownership post-transaction.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37427#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37427\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37427#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1604.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1604.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37427#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acquisition of a 95.09% stake in Shanghai-based LaNova Medicines Ltd for USD 950.92 million. After deducting LaNova's USD 450 million cash and equivalents, the net transaction value stands at USD 500.9 million. Sino Bio, which previously held 4.91% of LaNova, will gain full ownership post-transaction.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37427","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million","og_description":"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acquisition of a 95.09% stake in Shanghai-based LaNova Medicines Ltd for USD 950.92 million. After deducting LaNova's USD 450 million cash and equivalents, the net transaction value stands at USD 500.9 million. Sino Bio, which previously held 4.91% of LaNova, will gain full ownership post-transaction.","og_url":"https:\/\/flcube.com\/?p=37427","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-16T08:00:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1604.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37427#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37427"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million","datePublished":"2025-07-16T08:00:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37427"},"wordCount":166,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37427#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1604.webp","keywords":["Biotech","Finance","HKG: 1177","LaNova Medicines","Sino Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37427#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37427","url":"https:\/\/flcube.com\/?p=37427","name":"Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37427#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37427#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1604.webp","datePublished":"2025-07-16T08:00:29+00:00","description":"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acquisition of a 95.09% stake in Shanghai-based LaNova Medicines Ltd for USD 950.92 million. After deducting LaNova's USD 450 million cash and equivalents, the net transaction value stands at USD 500.9 million. Sino Bio, which previously held 4.91% of LaNova, will gain full ownership post-transaction.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37427#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37427"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37427#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1604.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1604.webp","width":1080,"height":608,"caption":"Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37427#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1604.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37427"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37427\/revisions"}],"predecessor-version":[{"id":37430,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37427\/revisions\/37430"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37429"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}